A second-generation eIF4A RNA helicase inhibitor exploits translational reprogramming as a vulnerability in...

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Triple-negative breast cancer (TNBC) presents significant therapeutic challenges due to its heterogeneity and propensity for metastasis.
• Current therapies for macro-metastatic TNBC are limited, necessitating novel treatment strategies.
• Aberrant mRNA translation is a recognized driver of cancer progression and a potential therapeutic vulnerability.

Purpose of the Study:

• To develop a novel therapeutic agent targeting mRNA translation for macro-metastatic TNBC.
• To investigate the efficacy and safety of the orally bioavailable rocaglate derivative, MG-002.
• To evaluate MG-002's potential to overcome TNBC heterogeneity and inhibit both primary tumor growth and metastasis.

Main Methods:

• Development of MG-002, a rocaglate-based inhibitor of eukaryotic translation initiation factor (eIF) 4A RNA helicase.
• Assessment of MG-002's ability to inhibit mRNA translation and ribosome recruitment/scanning.
• Evaluation of MG-002's anti-tumor efficacy and anti-metastatic activity in preclinical TNBC models.
• Toxicological assessment of MG-002 in vivo.

Main Results:

• MG-002 potently inhibited mRNA translation in TNBC cells.
• MG-002 demonstrated significant inhibition of primary TNBC tumor growth in preclinical models.
• MG-002 effectively attenuated metastasis in preclinical TNBC models without causing overt toxicity.
• MG-002 exhibited superior properties compared to existing eIF4A inhibitors in preclinical settings.

Conclusions:

• MG-002 is a promising orally bioavailable therapeutic lead for macro-metastatic TNBC.
• Targeting mRNA translation with MG-002 offers a viable strategy to combat TNBC heterogeneity and metastasis.
• The findings support further clinical investigation of MG-002 for TNBC and other cancers.